Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

European Respiratory Journal

Volumn 32, Issue 4, 2008, Pages 924-930

  Wu, S G ^a   Gow, C H ^b   Yu, C J ^a   Chang, Y L ^a   Yang, C H ^a   Hsu, Y C ^a   Shih, J Y ^a   Lee, Y C ^a   Yang, P C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b LOTUNG POH AI HOSPITAL   (Taiwan)

Author keywords

Epidermal growth factor receptor; Lung cancer; Mutation; Pleural effusion

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; ASIA; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION RATE; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; RECEPTOR GENE; SEX DIFFERENCE; SMOKING; THORACOCENTESIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PLEURAL EFFUSION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 58749093115     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00167407     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-2246.
5. van Puijenbroek R, Bosquee L, Meert AP, et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J 2007; 29: 128-133.
6. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
8. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
10. Clinical presentation of non-small cell carcinoma of the lung. In:. Pass HI, Johnson DH, eds. Lung Cancer: Principles and Practice. 3rd Edn. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 291-303.
11. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J 1997; 10: 1701-1702.
12. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multi-functional angiogenic cytokine. EXS 1997; 79: 233-269.
13. Cheng D, Rodriguez RM, Perkett EA, et al. Vascular endothelial growth factor in pleural fluid. Chest 1999; 116: 760-765.
14. Hsieh WY, Chen MW, Ho HT, You TM, Lu YT. Identification of differentially expressed proteins in human malignant pleural effusions. Eur Respir J 2006; 28: 1178-1185.
15. Dai Y, Morishita Y, Mase K, et al. Application of the p53 and K-ras gene mutation patterns for cytologic diagnosis of recurrent lung carcinomas. Cancer 2000; 90: 258-263.
16. Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006; 119: 2353-2358.
17. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, Yang CT. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J 2006; 29: 373-379.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. American Thoracic Society, Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1987-2001.
20. Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006; 95: 1390-1395.
21. Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006; 97: 642-648.
22. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumour development. N Engl J Med 1988; 319: 525-532.
23. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997; 75: 429-439.
24. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005; 65: 7568-7572.
25. Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 6816-6822.
26. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 2006; 119: 1491-1494.
27. Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007; 173: 107-113.
28. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11: 1167-1173.
29. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006; 94: 896-903.
30. Haneda H, Sasaki H, Lindeman N, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 2006; 36: 69-75.
31. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-8203.
32. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93: 355-363.
33. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-8923.
34. Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 2005; 353: 207-208.
35. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
36. Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumour activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006; 12: 7117-7125.
37. Sasaki H, Endo K, Okuda K, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 2007; 134: 569-577.
38. Soh J, Toyooka S, Ichihara S, et al. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. Int J Cancer 2007; 121: 1162-1167.
39. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-6837.
40. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54: 707-710.
41. Sack U, Hoffmann M, Zhao XJ, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005; 25: 600-604.
42. Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol 2006; 17: 1853.
43. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-2501.